I-Mab

IMAB

US44975P1030

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
1.6 ^USD	+6.67%		-4.19%	-15.79%

06/06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
05/06	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Tranche Update on I-Mab's Equity Buyback Plan announced on August 17, 2023.

April 30, 2024 at 04:31 pm IST

From August 1, 2023 to December 31, 2023, the company has repurchased 3,391,244 shares, representing 4.09% for $4.85 million. With this, the company has completed the repurchase of 3,391,244 shares, representing 4.09% for $4.85 million under the buyback announced on August 17, 2023.

Latest news about I-Mab

I-Mab Appoints Phillip Dennis as Chief Medical Officer	06/06	CI
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06	CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.	30/04	CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.	30/04	CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 17, 2023.	30/04	CI
Verastem Names John Hayslip as Chief Medical Officer	19/04	MT
I-Mab Announces Chief Medical Officer Changes	16/04	CI
I-Mab Completes Business Divestiture in China	03/04	MT
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04	CI
I-Mab Announces Executive Resignation	01/04	CI
Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	18/03	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	15/03	MT
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02	RE
I-Mab Divests China Operations, Shifts Focus to US Market	09/02	MT
ADRs Close Higher, Renalytix PLC Climbs 96.9%	09/02	DJ
Biotech firm I-Mab to divest China operations, shift focus to US	07/02	RE
Biotech firm I-Mab to divest China operations	07/02	RE
I-Mab Announces Board Changes , Effective February 10, 2024	07/02	CI
I-mab Biopharma Co., Ltd. agreed to acquire I-Mab Biopharma Co., Ltd. from I-Mab for $80 million.	07/02	CI
I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab	07/02	CI
I-Mab Announces Chief Financial Officer Changes	06/02	CI
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading	11/01	MT
ADRs Slump; FLJ Group Declines 21%	03/01	DJ

Chart I-Mab

Duration

Period

More charts

Company Profile

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Companyâs pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for I-Mab

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.6 USD

Average target price

7.25 USD

Spread / Average Target

+353.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
I-MAB	-15.79%	13Cr
ELI LILLY AND COMPANY	+56.89%	82TCr
NOVO NORDISK A/S	+39.52%	63TCr
JOHNSON & JOHNSON	-6.55%	35TCr
MERCK & CO., INC.	+15.99%	32TCr
ABBVIE INC.	+7.92%	30TCr
ASTRAZENECA PLC	+13.74%	24TCr
NOVARTIS AG	+13.83%	22TCr
ROCHE HOLDING AG	-0.49%	22TCr
AMGEN INC.	+7.94%	17TCr

Other Pharmaceuticals

I-Mab

Equities

IMAB

US44975P1030

Pharmaceuticals

Tranche Update on I-Mab's Equity Buyback Plan announced on August 17, 2023.

EPS Revisions